B-019

N/A

Report date: 2026/04/29 20:02:18

Base Information

Drug NameB-019
Drug Alias Name靶向CD19和CD22的嵌合抗原受体自体T细胞注射液B-019
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD19Anti-CD22
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLupus Erythematosus, SystemicLymphoma, B-CellLymphoma, Non-Hodgkin +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Pharmaceuticals Holding Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSPH Biotherapeutics (Shanghai) LtdShanghai Pharmaceuticals Holding Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicLymphoma, B-CellLymphoma, Non-Hodgkin +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A